Losartan ameliorates TGF-β1–induced CFTR dysfunction and improves correction by cystic fibrosis modulator therapies

por Kim, Michael D., Bengtson, Charles D., Yoshida, Makoto, Niloy, Asef J., Dennis, John S., Baumlin, Nathalie, Salathe, Matthias
Publicado 2022

An Open Label Trial to Assess Safety of Losartan for Treating Worsening Respiratory Illness in COVID-19

por Bengtson, Charles D., Montgomery, Robert N., Nazir, Usman, Satterwhite, Lewis, Kim, Michael D., Bahr, Nathan C., Castro, Mario, Baumlin, Nathalie, Salathe, Matthias
Publicado 2021

Losartan in hospitalized patients with COVID-19 in North America: An individual participant data meta-analysis

por Di Stefano, Leon, Ram, Malathi, Scharfstein, Daniel O., Li, Tianjing, Khanal, Preeti, Baksh, Sheriza N., McBee, Nichol, Bengtson, Charles D., Gadomski, Anne, Geriak, Matthew, Puskarich, Michael A., Salathe, Matthias A., Schutte, Aletta E., Tignanelli, Christopher J., Victory, Jennifer, Bierer, Barbara E., Hanley, Daniel F., Freilich, Daniel A.
Publicado 2023